Iovance's Phase 2 Lifileucel Plus Pembrolizumab Delivers 62.5% ORR And 29.2% Complete Response Rate In Frontline Advanced Melanoma, With Median OS Not Yet Reached At 50.9 Months

뉴스 본문을 불러오고 있어요.

Iovance's Phase 2 Lifileucel Plus Pembrolizumab Delivers 62.5% ORR And 29.2% Complete Response Rate In Frontline Advanced Melanoma, With Median OS Not Yet Reached At 50.9 Months | 웨이프 WAPE

Iovance's Phase 2 Lifileucel Plus Pembrolizumab Delivers 62.5% ORR And 29.2% Complete Response Rate In Frontline Advanced Melanoma, With Median OS Not Yet Reached At 50.9 Months

기사 요약

관련 종목

댓글 —